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S..y Enzymes which traditionally have played no role in cel-irected cytotoxicity are finding their way
into schemes for prodrug activation and immunotoxins owing to such usefl enzymatic activity. Alaline
phophatase, carboxypeptidases, D-ghucosiaes and P-lactamases among many others are being utiised to
regenrate potent anti-caner drugs or toxic small molecusl from precursors in a bid to enhance their activity
in tumours. These prodrug activation systems reqmre the pretargeting of the enzyme to the surface of a
tumour cel, usually by an antibody or its immunoreactive fragment. A recent novel approach proposes the
intracllular delivery of approprite enzymes, such as phosphodiesterases, to particular celular compartments.
Tbere, enzyme activity can cause substantie damag resulting in cell death. Cell targetig of mammahan
phosphodiesterases promises to improve upon conventional immunotoxins because of their increased cytotox-
icity when tared to the apropte cmpartment and their expected lack of, or lower, immunogenicity in
clinical use,
The toxicities associated with conventional cancer
chemotherapy arise primarily from the lack of specificity for
tumour cells. Most of the presently available drugs are
designed to be selectively toxic to rapidly dividing cells
(Valeriote & Putten, 1975). This results in a low therapeutic
index, which causes unacceptable damage to normal organs,
limiting the drug dose that can be a
A variety ofapproaches are under development to improve
the effectiveness and tumour cell specificity of cancer treat-
ment. Many such methods involve monoclonal antibodies
and offer attractive means of directing to a tumour toxic
agents such as drugs, radioisotopes, protein cytotoxins,
cytokines, effector cells of the immune system or, as in this
review, enzymes.
The concept of targeting enzymes to tumour cells can be
divided into two quite different approaches (Figure 1). Direc-
ting enzymes which catalyse precursor drug conversion into
active drug at the site of a tumour [known as prodrug
activation therapy, antibody-directed enzyme prodrug
therapy (ADEPT) or antibody-directed catalysis (ADC)]
entails using whole antibodies (or their fragments) raised
against tumour-associated antigens to deliver enzymes
specifically to tumour cells and catalyse the desired conver-
sion reaction in situ. The prodrug is designed to be a subs-
trate for the chosen enzyme. This work is now well advanced,
with many examples of systems already tested in preclinical
models and some entering clinical trials.
The second and possibly more novel approach is that of
targeting mammalian enzymes, which are usually non-
cytotoxic and non-immunogenic, intenally to a particular
cell compartment where they can catalyse a reaction resulting
in cell death. This method is analogous to that of
immunotoxins, naturally occurring cytotoxic proteins of
bacterial, plant or fungal origin that are directed inside target
cells and cause death as a result ofa specific, potent chemical
reaction (for example, the ribosylation of elongation factor 2
by Pseudomonas exotoxin).
P.radrug activatim system
Tumour antigens which do not readily internalse or cycle to
and from the cell surface lend themselves as targets for
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prodrug activation systems. Such antigens are human car-
cinoembryonic antigen (CEA) and human chorionic gonado-
tropin (hCG).
Monoclonal antibodies remain the choice vehicle for
targeting, because of their high specificity as well as ease of
isolation and manipulation (K6hler & Milstein, 1975; Wald-
mann, 1991). However, experments using radiolabelled
antibodies have shown that distribution of whole or even
fragments ofantibodies is not always optimal. Owing to their
large size (150 kDa for IgG), antibodies penetrate slowly into
solid tumour masses and are resticted to areas in the tumour
which are near blood vessels (Del Vicchio et al., 1989).
Antibodies are clared slowly from the circulation, resulting
in a high background level. A further limitation is that not
all the cels in the tumour are detected. This is because of the
heterogeneous expression of tumour-associated antigens, that
is the existence of a population of antigen-negative tumour
cells (Edwards, 1985). As monoclonal antibodies entered
cinic use it became aprent that 100-1,000 times less
antibody is taken up by tumours than in animal xenograft
studies (Epenetos et al., 1986).
These obsations gave rise to the concept of directed
prodrug activation therapy (Bagshawe, 1987). By way of a
monoclonal antibody (or any other cell-specific ligand), an
enzyme can be accmulated within a tumour at a
significntly higher concentration than in other tissues. The
long half-life ofthis non-toxic molecule would allow maximal
loading at the tumour site without significant background
toxicity. The systemic administration of a suitably designed
prodrug would generate a small. highly toxic drug within the
tumour which is able to diffuse into the mass. Such drug
moleules would kill tumour ells inaccesble to larger
molecules, and neighbouring antigen-negative tumour cells
would also be kiled (by-stander effect), overcomng the prob-
lems of poor penetration and antigen heterogeneity. Since
enzymes are catalytic proteins with high turnover, many
active drug molecules would be generated by one enzyme
molecule, thereby amplifying the number of toxic moleules
at the site of the tumour, compensating for the low initial
uptake. Some of the more extensively studied enzyme-
mediated prodrug activation schemes (Table I) are described
below. All the systems described except the P-glucuronidase
fusion of Bosslet et al. (1992) involve chemical conjugation of
the antibody and enzyme partners using stable non-reducible
linages. Each of these schemes has its strengths and limita-
tions.
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Fge 1 Alternative approaches to targeted enzyme therapy. a, Enzymes can be localised to the surface of the target cell and
activate systemically administered prodrug. The toxic drug can then diffuse inside the tumour. b, Certain cell-bound molecules are
taken into the cell by antigens and can be used to introduce enzymes, with toxic activities, into cellular compartments, e.g.
ribonuclease activity in the cytosol.
Generatiom of highly reacte toic species iA situ
Reduced oxygen species have been shown to participate in
the anti-cancer action of chemotherapeutic agents, radiation
therapy and host cell defence mechanisms. The molecules
implicated are peroxide, superoxide and hydroxyl radicals.
These and other small, toxic species such as cyanide have
been incorporated into prodrug activation systems.
Oxidases
The first example of targeted enzyme therapy was demon-
strated by Philpott et al. (1973), who chemically conjugated
glucose oxidase, which generates peroxide from glucose, to a
polyclonal anti-hapten antibody. The conjugate was tested on
hapten-substituted cells, but was not significantly cytotoxic
on the addition of glucose. This may have been because of
the low enzymatic activity of the conjugate or the lack of
sensitivity of the cell line, since other workers have had more
success with this particular system (Stanislawski et al., 1989).
However, when this sytem was coupled to lactoperoxidase
and iodine, a marked increase in cellular toxicity was
observed. Thus was demonstrated immunospecific cellular
iodination, with cytotoxic effects.
The glucose oxidase system has also been investigated by
Muzykantov et al. (1988) using polyclonal and monoclonal
antibodies. Significant cytotoxicity was observed using a
polyclonal antibody preparation, but studies using specific
a
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Table I List of the prodrug activation systems currently under development, with the antigens and antibodies used. See text for
references
Antibodylantigen Enzyme Prodrug Active drug
MAb 097/CDw52 Glucose oxidase and Glucose (dextrose) Hydrogen peroxide and toxic
pan-leucocyte) lactoperoxidase sodium iodide iodine species
MAb 8A/plasma Xanthine oxidase Xanthine, hypoxanthine Hydrogen peroxide, hydroxyl
cell-associated antigen and oxygen radicals
MAbs W14A and SBIO/ Carboxypeptidase G2 Benzoic acid mustards-glutamic acid Benzoic acid
chorionic gonadotropin mustards
MAb L6 (against a carbohydrate Alkaline phosphatase Etoposide phosphate, doxorubicin Etoposide, doxorubicin,
antigen on human carcinomas) phosphate, mitomycin phosphate mitomycin
phenol mustard phosphate Phenol mustard
MAb BW431/26/ Alkaline phosphatase Etoposide phosphate Etoposide
carcinoembryonic antigen (CEA)
MAb KS1/4/UCLA-P3 Carboxypeptidase A Methotrexate-alanine Methotrexate
human lung adenocarcinoma
MAb L6 (see above) Cytosine deaminase 5-Fluorocytosme (5-FC) 5-Fluorouracil (5FU)
MAb L6 (see above) Penicillin amidase Doxorubicin-phenoxyacetamide Doxorubicin
Melphalan-phenoxyacetamide Melphalan
Palytoxin-4 hydroxyphenoxyacetamide Palytoxin
MAb H17E2/ -Glucosidase Amygdalin Cyanide
anti-placental alkaline phosphatase
MAb 323/A3 (against a pan- -GIucuronidase Epirubicin-glucoronide Epirubicin
carcinoma membrane glycoprotein
MAb 12.8/ S-Glucuronidase Phenol mustard glucoronide Phenol mustard
colon carcinoma
MAb BW431/26, Fa A-Glucuronidase Daunomycin-glucoronide Daunomycin
anti-CEA Adriamycin-glucoronide Adriamycin
MAb L6 [see above, F(ab')J -Lactamase Phenylediamine mustard Phenylenediamine mustard
cephalosporin
No antibody in study P-Lactamase Vinca-cephalosporin Vinca alkaloid
P-Lactamase Nitrogen mustard-cephalosporin Nitrogen mustard
Nitroreductase CB1954 5-aziridin 2,4-hydroxyamino
(5-aziridin 2,4-dinitrobenzamidine) 2-nitrobenzamidine
monoclonal antibodies have suggested that the more potent
mode of action could be due to its internalisation, the con-
jugate acting in an immunotoxin-like manner (see below) by
generating intracellular peroxides, rather than activating pro-
drugs at the cell surface (Muzykantov et al., 1990).
The enzyme xanthine oxidase generates reduced oxygen
species from xanthine or hypoxanthine. The potency of the
free radicals formed was enhanced by the presence of
chelated iron. When conjugated to a monoclonal antibody
against a human plasma cell-associated antigen it formed an
effective prodrug activation system which was selectively
cytotoxic to plasma cells but was non-toxic to myeloid
precursors (Dinota et al., 1990). Its usefulness was shown in
the ability to purge neoplastic plasma cells from bone mar-
row suspensions in vitro, sparing the stem cells for
autologous bone marrow transplantation. Similar systems to
deplete T cells from bone marrow have been developed using
the glucose oxidase/lactoperoxidase system (Ito et al., 1990).
Unfortunately, these types of systems would find little use in
vivo owing to the presence of neutralising serum enzymes
such as catalase and superoxide dismutase. Alternatively,
such neutralising properties have been put to use by targeting
antibody-catalase conjugates to cells in order to protect
them by positive selection (Sakharov et al., 1987).
Studies on oxidative enzyme conjugates have shown that
very few neighbouring cells are killed by their action, pro-
bably explaining their success at purging specific populations
of cells from a mixture. This may be because of extremely
short half-life of the toxic molecules produced. In another
system, a very small toxic species is generated by prodrug
activation which is not affected by the neutralising action of
serum enzymes and may have a half-life long enough to have
a bystander killing effect. This is the cyanide generation
system devised by Rowlinson-Busza et al. (1992) (antibody-
guided enzyme nitrile therapy).
Antibody-guided enzyme nitrile therapy
This system, known as AGENT, is based upon the enzyme
P-glucosidase conjugated to a tumour-specific monoclonal
antibody. The P-glucosidase from sweet almonds has a broad
substrate specificity enabling it to catalyse the conversion of
a disaccharide, amygdalin to glucose, benzaldehyde and
hydrogen cyanide (Figure 2). Amygdalin has been used,
ineffectively, as an anti-cancer treatment under the name
Laetrile. Its poor activity was due to the slow, untargeted
release of the toxic moiety, cyanide. Human tumours do not
express a P-glucosidase which is capable of activating amy-
gdalin. With the targeted system, cyanide can diffuse into
tumour and surrounding cells and kill them by inhibiting
mitochondrial respiration. The work has already produced
encouraging results: cell-bound antibody-$-glucosidase con-
jugate can enhance the cytotoxicity of amygdalin to that of
the level of cyanide alone in vitro. This results in a 1,000-fold
enhancement of toxicity (Rowlinson-Busza et al., 1992).
Cyanide is not as toxic as most conventional drugs (IC50
2009LM), but generation of a high enough concentration
within the tumour should have beneficial results. These high
doses can be realised, as amygdalin itself is non-toxic.
A paradigm of the prodrug activation system that can be
tested easily in the clinic is that of intravesicle tretment of
bladder cancer: high concentrations of amygdalin can be
administered and the antigen is easily accessible.
The genes for specific cyanogenic A-glucosidases have been
cloned, making it feasible to construct recombinant anti-
body-p-glucosidase fusion proteins. Recombinant creation of
molecules suitable for prodrug activation is a more exact
method than chemical conjugation, because of the unwanted
side-reactions which occur upon chemical cross-linking. Also,
genetic manipulation can allow molecules to be altered and
tailored to the required function, for example decreasing the
size of the fusion protein by using single-chain antibodies or
altering substrate specificity by active-site protein engineer-
ing. The recombinantly produced molecule should have a
much higher activity, as was found for the P-glucuronidase
fusion protein (Bosslet et al., 1992).
Regeneration ofconventional an-cancer drugs in s#iS
A great deal of effort has been placed into improving the
action of conventional chemotherapy drugs such asTARGETING ENZYMES FOR CANCER THERAPY 789
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Fge 2 Examples of the structures of three of the prodrugs reviewed and their enzymic conversion to active drugs.
alkylating agents and DNA synthesis inhibitors, by aiming to
generate them at high concentrations in tumour cells in
preference to other organ sites. The similarities between nor-
mal and neoplastic cells have made it difficult to identify
specific tumour-expressed enzymes which may be able to
activate prodrugs. Subcutaneous placement of encapsulated
enzymes into tumours, followed by the administration of the
prodrug, has been one attempt (e.g. cytosine deaminase).
This, of course, is ineffective against disseminated disease.
Antibody delivery of a myriad of enzymes has made it pos-
sible to activate many different prodrugs, which are relatively
non-toxic forms of pre-existing anti-cancer drugs. The
derivatisation of an active drug can lower its toxicity in a
number of ways. For example, the addition of a charged
group can reduce its ability to permeate cells, the addition of
a chemical group may reduce the reactivity of the drug or the
alteration of the drug may reduce its affinity for the cellular
target. With this approach, correct timing of antibody-
enzyme and prodrug administration can lead to both a high
level of cytotoxicity at all accessible tumour deposits
systemically and low toxicity elsewhere.
Alkalinephosphatase
Many established chemotherapeutic drugs have been phos-
phorylated to form much less active prodrugs suitable for
regeneration by the enzyme alkaline phosphatase, which
hydrolytically removes phosphates (Figure 2). The phos-
phorylated version of the first drug to be used, etoposide, is
more than 100-fold kss toxic to a human carcinoma cell line
(Senter et al., 1988). When alkaline phosphatase was directed
to tumour cells in vitro and in vivo by the tumour-specific
monoclonal antibody L6, significant immunospecific anti-
tumour activity was seen. The alkalie phosphatase used
here, however, was from calf intestine. It is not ideal for
therapy, as unacceptably high levels of alkaline phosphatase
accumulate in many tissues, causing a great deal of prodrug
to be prematurely activated. Similar work on this system
using an anti-CEA antibody has shown that prolonged
exposure to the etoposide-phosphate prodrug is almost as
toxic as the activated drug (Haisma et al., 1992a). Other
systems have sought to overcome this major problem, and it
is likely that the use of alkaline phosphatase, although suc-
cessful in demonstrating the concept, will be superseded by
the use of better suited enzymes.
Bispecific antibodies have been used successfully to deliver
cytotoxins such as saporin to tumour cells (Glennie et al.,
1988). This approach has also been incorporated in a pro-
drug activation system to deliver alkaline phosphatase to a
Hodgkin's disease-derived tumour cell line (Sahin et al.,
1990). An anti-alkaline phosphatase/anti CD30 bispecific
antibody, expressed from a hybrid hybridoma, was prein-
cubated with the enzyme before the whole assembly was
tested on antigen-positive cells. The prodrug, mitomycin
phosphate, was activated to levels similar to those seen with
the chemical conjugate approach. This method, which can be
applied to other enzymes, eliminates the need for chemical
cross-linking, which can impair both the antigen binding and
enzymatic activities.
Carboxypeptidase G2
One of the key features of the prodrug activation approach
should be that the enzyme does not occur naturally in nor-
mal tissues. Prokaryotes express many such unique enzymes
and were the source of the glutamic acid exopeptidase, car-
boxypeptidase G2 (from Pseudomonas), which forms the
basis of the approach pioneered by Bagshawe et al. (1988).
This enzyme has been chemically linked to the F(abj)
fragments of an anti-hCG or anti-CEA antibody and used to
activate glutanuc acid derivatives of various nitrogen mus-
tards (Figure 2). The prodrugs were approximately 100-fold
less toxic than the parent drugs. This work is now well
advanced, and a substantial amount of in vivo preclinical
work has been carried out. In a subcutaneous choriocar-
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was observed in mice which had received the conjugate fol-
lowed by the prodrug under different treatment regimens.
The best one, resulting in eradication of a tumour xenograft,
was obtained when 3 x 10 mg per mouse doses of prodrug
were administered 72 h after 50 enzyme units of
antibody-enzyme conjugate was injected (Springer et al.,
1991). The tumor was previously shown to be resistant to
conventional chemotherapy (e.g. methotrexate and actino-
mycin D). Measurement of the levels ofenzyme, prodrug and
drug in tumours and normal tissues has shown that the
tumour had the highest ratio of active drug to prodrug,
implying that site-specific activation is occurring. However,
there was a significantly higher absolute amount of active
drug in the liver, kidney and blood, suggestng that the
prodrug was being activated elsewhere. A three-phased
system has been developed to combat the high background
levels, by injecting a clearing antibody (Sharma et al., 1991).
This takes the form of a galactosylated anti-enzyme antibody
antibody (raised against the active site of the enzyme). This
large antibody 'mops up' crculating conjugate and is not as
accessible to the tumour as the initial enzyme conjugate. It is
then cleared rapidly by the liver via galactose receptors and is
not active in that organ. This allows the prodrug to be
administered earlier (within 24 h) with similar results as
before. This ADEPIT approach is under further development
with many prodrug/drug combinations being tested for
efficacy.
Carboxypeptidase A
The anti-folate drug methotrexate can be derivatised by the
addition ofalanine to its carboxylic acid group, resulting in a
lowering of its ID_% by almost 200-fold (to 8.8 x 10-5 M).
Bovine pancreas carboxypeptidase A can remove alanine
residues from these molecus, enabling the active drug to be
internalised by folate transport systems. This enzyme was
coupled to an antibody directed against a lung adenocar-
cinoma cell line (UCLA-P3) in a prodrug activation system
(Haenseler et al., 1992). However the antibody-enzyme con-
jugate could only reactivate the prodrug moderately (6-fold)
and, as with many of these systems, high cytotoxicity was
found with prolonged exposure to the prodrug. The authors
suggest that cell-surface peptidases, a slow uptake or folate
starvation caused by the competing prodrug may be the
cause. Other derivitised folate antagonists may give better
results in future.
PGlucuronidase
Mice bearing well-established PC5 plasma tumours were
found to express high levels of P-glucuronidase, which were
able to activate aniline mustard prodrugs derivtised (in vivo
by the liver) with P-glucopyranoside (Connors & Whisson,
1966). This strategy proved ineffective in humans because of
the low levels ofP-ghx-uronidase. This led the way to systems
involving targeted P-glucuronidases (GUS). The Escherichia
coli and human form of the enzyme have both been used. A
chemical conjugate of the E. coli enzyme to a pan-carinoma
antibody is able to activate the glucuronide form of the drug
epirubicin (Haisma et al., 1992b). Epirubicin-glucuronide
(epi-glu) is a metabolicay inactivated form of epirubicin
isolated from the urine of patients treated with the conven-
tional anti-cancer drug (1 mg can be purified per patient). It
is 100- to 1,000-fold less toxic than the metabolically active
drug, a more impressive value than most of the prodrug
examples described here (IC50 of epi-glu is 2011M). The E.
coli enzyme has also been used in conjunction with aniline
mustard prodrugs, which are over 500-fold less toxic than the
parent drug (Roffler et al., 1991). It is also suggested that in
this system the liver enzyme UDP gluconosyltransferase may
convert cirulating active drug back into prodrug. Overall,
these systems, although in early developmental stages, seem
to have many advantages over the other approaches: the
endogenous enzyme is present intracellularly and not exposed
to the prodrug and the prodrugs are 10-100 times more
non-toxic than other prodrug/drug combinations. Also, the
pH microenvironment around the tumour is acid to neutral
(Tannock & Ratin, 1989) and not optimal for enzymes such
as alkaline phosphatase, but suitable for GUS (E. coli GUS
pH optimum is 6.8, human GUS pH optimum is 5.4). Lastly,
the use of the human enzyme may reduce immunogenicity
permitting repeated administration. A human anti-CEA
Fab'-human GUS fusion protein has been constructed and
expressed in baby hamster kidney transfectomas (Bosslet et
al., 1992). Some impressive results in tumour xenograft
studies have been achieved using this fusion protein and
doxorubicin-glucuronide as a prodrug (Bosslet et al., 1994).
This report showed that very high tumour-normal organ
ratios of the antibody-enzyme fusion protein could be
achieved by 7 days, allowing specific prodrug activation.
Significant tumour growth delays of around 30 days were
seen m tins system.
It has been reported that more effective prodrug activation
can be achieved in vitro using liposomes. In this case large
aggregates consisting of a liposome with some 400 Fab'
fragments and 20 P-glucoronidases has been made (Vinger-
hoeds et al., 1993). Whether this assembly is effective in vivo
despite its large size remains to be seen.
Cytosine deawinase
Fungi are intoxicated by the drug 5-fluorocytosine (5-FC),
through its intracellular conversion to 5-fluorouracil (5-FU)
by the fungus-specific enzyme cytosine deaminase (CDase).
This forms the basis of an antifungal treatment and appears
to be a suitable drug for a prodrug activation system. The
5-FC prodrug is non-toxic at up to 200mM, whereas the
5-FU drug has an IC50 of 20jAM in vitro. Although not as
toxic as some anti-cancer drugs (e.g. methotrexate ICv is
0.05jLM) the low toxicity and established clinical use of 5-FC
make it an attractive molecule which may be effective if
generated at high enough concentrations. Unfortunately,
many cancers develop drug resistance to 5-FU. Work using
the L6 antibody and CDase purified from bakers' yeast has
shown immunospecific cytotoxciaty (Senter et al., 1991). This
enzyme has also been the subject of a gene therapy approach
to targeting enzymes (see below).
Penicillin amidase
This enzyme is used industrially to hydrolyse the phenox-
yacetamide group from penicillin V to yield 6-amino-
penicillanic acid. The anti-cancer drugs doxorubicin and
melphalan have been derivatised with p-hydroxyphenoxy-
acetamide to form substrates (DPO and MPO respectively)
which are readily converted to the active drug by the enzyme
(Kerr et al., 1990). The DPO prodrug is 80-fold less toxic
than doxorubicin (IC50 30 nM) whereas the MPO prodrug is
more than 1,000-fold less toxic than melphalan against
tumour cell-lines. However, especially in the case of the MPO
prodrug, the antibody-enzyme conjugate was not able to
liberate the active drug from the prodrug effectively in order
to produce a cytotoxic effect, suggesting that the enzyme
catalysed the reaction too slowly to be useful. This highlights
the importance of having an enzyme with a high turnover in
order to generate high concentrations of active drug.
Penicillin-G-amidase has also been used in this context to
activate the prodrug palytoxin (Bignami et al., 1992).
P-Lactamase
The O-lactamases from E. coli, Enterobacter cloacae and
Bacillus have good cephalosporinase activity and are able to
accommodate a wide range of 3'substituents in the active site
yet retain the ability to cleave the A-lactam ring. This activity
enables the enzyme to release the cephalosporin group from a
wide range of prodrugs, including nitrogen mustard and
vinca allkaloid derivatives (Alexander et al., 1991). In addi-
tion, eukaryotic cells have no such enzyme or related enzyme
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vivo. Examples of its use in vitro with the L6 monoclonal
antibody have shown good targeted prodrug activation
(Svensson et al., 1992). The prodrug tested was a cephalo-
sporin mustard which released the active drug phenyl-
enediamine mustard (50-fold more toxic) in the presence of
an antibody-p-lactamase conjugate on antigen-positive
tumour cells. The CEA antigen has also been the target of a
similar system with different prodrugs (Meyer et al., 1992).
The importance and usefulness of this partcular system may
come about through the use of a cocktail of different pro-
drugs, all of which can be activated by the -lactamase, to
release a panel of active drugs which can act independently
or synergistically.
Nitroreductase
The anti-cancer drug CB1954 (a dinitrobenzamide) is a
monofunctional alkylating agent. It is toxic to rat Walker
256 tumour cells and some hepatomas owing to its activation
by the high levels of the enzyme DT diaphorase, forming the
hydroxylamino nitrobenzamide (a bifuwcional DNA cross-
linking agent). Some human colon tumour cell ines have
been tested and found to have a degree of nitroreductase or
diaphorase activity, enough to makle them sensitive to the
drug (Sunters et al., 1991). An E. coli enzyme, nitroreductase,
has been isolated which can catalyse the same reaction more
efficiently, thus opening up the possibility of a prodrug
activation scheme, whereby any cell can be made sensitive to
its effects providing a suitable antibody is available (Anlark
et al., 1992).
Pmdr.g activa st the futwe
Immunotherapy using plant and microbial cytotoxins is well
advanced compared with the types of systems described
above. Several phase I and II clinical trials have highlighted
the problems of immunogenicity, with patients eLiciting
antibody responses to both the toxin and the antibody por-
tions (Byers et al., 1989; Weiner et al., 1989, Vitetta et al.,
1993). Such responses have also been noticed in prodrug
activation therapy with carboxypeptidase G2 (Bagshawe et
al., 1991). The result is less effective therapy owing to fast
clearance of the immunoconjugate and some adverse side-
effects. Some of the methods described here have used human
enzymes and human antibody fragments (Bosslet et al.,
1992). However, one of the most important points of this
approach is that the enzyme activity targeted to the tumour
cells must not exist elsewhere where it can cause tissue
damage. Such enzymes, unless they are of non-human origin,
are hard to find. Alternatives are to co-administer
immunosuppressive agents (Lzderman et al., 1988),
chemically modify proteins to become less immunogenic (e.g.
PEG derivatisation; Sehon, 1989), use smaller immunocon-
jugates, for example single-chain antibody fragments linked
to smaller enzymes, or design catalytic antibodies for pro-
drug activation (Miyashita et al., 1993) which are bifunc-
tional in nature, having one antigen-binding site that is
tumour specific and one site that can activate a prodrug.
Recombinant DNA technology is being used increasingly
in this area to produce antibody-enzyme chineric proteins.
The feasibility of constructing recombinant antibodies with
novel effector functions was demonstrated by Neuberger et
al. (1984), when an active antibody-nucease was created
and expressed in hybridomas. Now, 10 years on, it is com-
monplace. This approach circumvents the problems of con-
jugate heterogeneity and damaging side-reactions which
reduce the molecule's effectiveness. By suitable design and
some knowledge of the protein's three-dimensional structure,
chimeric antibody-enzyme molecules can be tailored for
different uses, e.g. the substrate specificity can be broadened
in order to be able to activate a wider range ofprodrugs (for
polyimmunochemotherapy) or the catalytic efficiency or
stability may be improved. It may also be possible to alter
the surface amino acids ofrecombinantly produced molecules
in order to make them less immunogenic by process known
as 'veneering' or 'humanising', which has already proved to
be quite effective for antibodies (Reichmann et al., 1988).
Finally, single-chain antibodies (scFvs: variable heavy and
variable light antibody domains linked by a flexible peptide
to form a univalent antigen-binding fragment) are emerging
as the most useful immunoreactive fragment for targeting
because of their small size (30 kDa) and ease of production
(Bird et al., 1988; Huston et al., 1988; Adams et al., 1993;
Chester et al., 1994).
Enzymes which render tumour cells susceptible to certain
prodrugs may also be introduced into the cytosol of the cell.
This forms the basis of a gene therapy approach to prodrug
activation therapy (Gutierez et al., 1992), in which the gene
for the enzyme is targeted to all cells using a suitable vehicle
(e.g. a retrovirus). Only in tumour cells will the enzyme be
expressed as it is under the control of a promoter which is
up-regulated or switched on in tumour cells (e.g. the c-erbB2
promoter in breast cancer, Harris et al., 1994). This ap-
proach, termed 'VDEFP for virally directed enzyme prodrug
therapy, is very much in the early stages of development, but
some results have been published using the enzyme thymidine
kinase from herpes virus to activate ganciclovir (Moolten,
1986) and cytosine deaminase to activate the prodrug 5-
fluorocytosine (Mulen et al., 1992; Harris et al., 1994). As
activation occurs intracellularly, the prodrug must be able to
permeate the cells. This approach seems promising there are
no immunogenicty problems whatever enzyme is used as it
never encounters the une system. A higher concentration
of enzyme within tumour cells may also be achieved, and
some by-stander killing effects have been observed. There is
no reason why this approach cannot be extended to delivery
of immunotoxin-like molecules (see below). A great deal of
work is in progress to fully understand the mechnis of
tumour-specific promoters to be able to ensure safe and
tumour-specific expression of these 'suicide genes'.
Tare o diesteraes for caacer therpy
Naturaly occurring proteins with inherent cytotoxic proper-
ties have long been used in immunotherapy (Vitetta et al.,
1993). These have all been of microbial or plant origin, and
problems with immunogenicity have been encountered in the
clinic (Gould et al., 1989; Weiner et al., 1989). Some of these
proteins (e.g. a-sarcin and mitogillin) depend on ribonuclease
activity for toxicity. A novel approach in this area has been
the use of mammalian enzymes, ideally human enzymes,
which are normally non-toxic but become extremely toxic
when redirected to the correct cellular compartment.
The enzymes of the vertebrate ribonuclease (RNAse)
superfamily make up the majority of such enzymes under
study. It has long been known that the enzyme bovine
sminal RNAse, the only dinric member of the family, has
anti-tumour activity by a so far unknown mechanism related
to its RNAse activity and dimeric structure (Laccetti et al.,
1992). In fact, artificially dimerised pancreatic RNAse
(RNAse A) is also cytotoxic to some tumour cell lines.
RNAse A has been used clinically in the treatment ofchronic
myelocyt leukaemia (Aleksandrowicz, 1958) and viral tick-
borne encephalitis (Glukhov et al., 1976) with no adverse
effects and some success. A ribonuclease called 'onconase'
isolated from bull frog oocytes is being studied as a specific
tumoricidal protein (Wu et al., 1993). Onconase has been
shown to act synergistically with the conventional anti-cancer
drugs tamoxifen, cisplatin and lovastatin (Mikulski et al.,
1992). An ovarian carc'inoma cell line (NIH-OVCAR-3) was
treated in vitro although it was previously chemothera-
peutically resistant. The authors suggest that the nature of
the synergistic action is the induction of apoptosis by the
drug combinations.
Eosinophils are a major line of host defence against
parasites. They contain granules which have two of the pro-
teims impicated in their cytotoxicity. EDN (eosinophil-
derived neurotoxin) and ECP (eosinophil cationic protein).792 M.P. DEONARAIN & A.A. EPENETOS
Both these proteins have RNAse activity and are homolo-
gous to RNAse A and wminal RNAse. Thus it is evident
that, under certain conditions, mammalian RNAses can be
cytotoxic. This was better demonstrated by work by Rybak
et al. (1991), showing that RNAse A is as toxic as ricin when
injected into Xenopus oocytes (IC5o of 30 pM). This work led
to the construction of an immunotoxin-like molecule in
which RNAse A was chemically conjugated to transferrin or
an anti-transferrin receptor antibody and was shown to be
cytotoxic to a cell line expressing transferrin receptors (New-
ton et al., 1992). Work has now progressed to the point
where a human antibody-human RNAse (angiogenin) has
been expressed in a hybridoma (Rybak et al., 1992) to form a
completely humanised immunotoxin.
A potential major improvement on this approach has been
devised using the gene for the dimeric bovine seminal RNAse
(Deonarain & Epenetos, 1994). An anti-tumour scFv,
directed against the human tumour-associated antigen
placental alkaline phosphatase (Epenetos et al., 1985) has
been fused to bovine seminal RNAse and expressed in E.
coli. After refolding the expressed protein, both ribonuclease
and antigen-binding activity can be recovered. The fusion
protein also shows signs of being dimeric. When tested on
antigen-positive cell lines, the fusion protein appears to be
cytotoxic at low concentrations (M.P. Deonarain & A.A.
Epenetos, unpublished work). It is hoped that the intrinsic
anti-tumour and immunosuppressive properties of this
enzyme and the ability to cross-link surface antigens would
make this chimeric molecule an effective alternative to con-
ventional immunotoxins.
Another phosphodiesterase that can be cytotoxic is deox-
yribonuclease I (DNAse I). When expressed in bacteria, it is
lethal to the cell, presumably because of the degradation of
exposed chromosomal DNA (Worrall & Connolly, 1990).
The process of apoptosis involves a DNAse I-like endo-
nuclease (Martin et al., 1994). A strategy based on this
observation would be to redirect the mammalian DNAse to
the nucleus of a tumour cell. Further trafficking to the
nucleus can be achieved using a nuclear localisation sequence
such as those found in transcription factors. Preliminary data
suggest that this approach may offer significant advantages in
the creation of highly specific and potent anti-cancer agents
(H. Linardou et al., unpublished results).
Gene therapy approaches to deliver suicde genes to tumour
cells may also be used to deliver cytotoxic enzymes. For
example, a gene encoding a deoxynbonuclease or a radical-
forming oxidase constructed with a leader sequence and a
nuclear localisation sequence should be cytotoxic to cells
which express them, owing to the nuclear delivery of an
enzyme which degrades DNA. Although DNA fragmentation
is not thought to be the cause of cell death in apoptosis, it is
evident that nucleases are normally excluded from the
nucleus, but actively recruited in apoptosis. There has
already been success in expressing scFvs against the HIV
antigen gpl20, inhibiting virus assembly in the endoplasmic
reticulum (Marasco et al., 1993). A DNAse approach would
require a little more intracellular targeting. Why stop at
enzymes? Intracellular expression of nuclear-targeted scFvs
against topoisomerases, DNA polymerases, etc., may be just
as toxic as conventional DNA replication-inhibiting drugs.
Couclusoas
The approaches to targeted enzyme therapy described here
show that different enzymatic activities can be harnessed for
different purposes. An increasing number of
antibody-enzyme conjugates for prodrug activation is emer-
ging enabling many of the presently available anti-cancer
drugs to be utilised more effectively. The advantages of
amplification of drug dose, by-stander cell killing and multi-
ple drug activation in some examples make this type of
therapy promising and may overcome some cases where drug
resistance is a problem. This is provided that suitable
antigens are available for exploitation. However, the inherent
complexity of this system, immunogenicity from the more
widely used microbial enzymes and the pharmacokinetics of
antibody-enzyme and prodrug administration are draw-
backs. Direct intoxication of tumour cells with normally
non-toxic 'mammalian' enzymes, such as phosphodiesterases,
which may be potentially less immunogenic molecules, is a
particularly attractive system. The real problem, as with all
the immunotoxin treatments, is the necessity of eradicating
all the important tumour cells in a population. Nevertheless,
this is not an insurmountable problem, as has already been
highlighted by the few but encouraging results obtained by
conventional albeit crude chemotherapy.
Many thanks to Gail Rowlinson-Busza and Robert Spooner for
useful comments on this manuscript.
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